Govt procures 11 mn shots from Serum, 5.5 mn doses from Bharat Biotech

Truman Slate

Days before the commencement of the nationwide Covid-19 vaccination drive, the Union Health Ministry said on Tuesday that 1.1 crore Covishield and 55 lakh Covaxin vaccines have been procured at a cost of Rs 200 and Rs 206 per dose, respectively.

“As many as 110 lakh (1.1 crore) doses of Covishield vaccine are being procured from the Serum Institute of India at a cost of Rs 200 per dose, excluding taxes. A total of 55 lakh doses of Covaxin vaccine are being procured from Bharat Biotech,” Union Health Secretary Rajesh Bhushan said during a press conference.


The cost of 38.5 lakh doses of Covaxin is Rs 295 per dose, excluding taxes. Bharat Biotech is providing 16.5 lakh doses of Covaxin free of cost to the Central government. Hence, the cost of Covaxin comes to Rs 206 per dose,” he added.

Vaccines have already reached some states.

Till 4 p.m., about 54,72,000 doses were received by the states and Union Territories. By January 14, 100 per cent doses will be received.

The much-awaited Covid-19 vaccination drive will kick-off on January 16. The Central government plans to vaccinate nearly 30 crore people in the first phase of the drive. Priority will be given to the healthcare and frontline workers who are estimated to be around three crore, followed by those above 50 years of age and the under-50 population with comorbidities numbering around 27 crore.

On January 3, two vaccines — Bharat Biotech’s Covaxin and Oxford-AstraZeneca’s Covishield manufactured by the Serum Institute of India — were approved for ‘restricted emergency use’. Few more vaccines are in the pipeline and are conducting trials.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Next Post

Buffett bets on big pharma and bails on banks

Mr Buffett’s firm experienced stakes valued at much more than $one.8bn each in AbbVie, Bristol-Myers Squibb and Merck at the conclude of the quarter, and about $136m in Pfizer. Berkshire omitted some private information with its program regulatory filing. The ninety-calendar year-old has been cautious in the course of the pandemic, […]